(Q33948597)

30 July 2017

1 reference

title

Herpes simplex virus infections. (English)

1 reference

30 July 2017

0 references

2

B Roizman

1 reference

30 July 2017

R J Whitley

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

30 July 2017

number of pages

6

1 reference

inferred from page(s)

published in

The Lancet

1 reference

30 July 2017

volume

357

1 reference

30 July 2017

issue

9267

1 reference

30 July 2017

page(s)

1513-1518

1 reference

Herpes simplex genes: the blueprint of a successful human pathogen

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Herpes vaccines: spinning a new DISC

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Latent herpes simplex virus in spinal ganglia of mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Herpes simplex virus type 2 in the United States, 1976 to 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

The natural history of recurrent herpes simplex labialis: implications for antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Genital herpes simplex virus infections: clinical manifestations, course, and complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Risk Factors for the Sexual Transmission of Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Virologic characteristics of subclinical and symptomatic genital herpes infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

A comparison between detailed and simple histories in the diagnosis of genital herpes complicating pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

1 reference

7 January 2021

Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Acyclovir prophylaxis of herpes-simplex-virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Vidarabine versus acyclovir therapy in herpes simplex encephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Genetically engineered HSV in the treatment of glioma: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

A variant of herpes simplex virus type 2 strain HG52 with a 1.5 kb deletion in RL between 0 to 0.02 and 0.81 to 0.83 map units is non-neurovirulent for mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

The herpes simplex virus type 2 (HG52) variant JH2604 has a 1488 bp deletion which eliminates neurovirulence in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Effects on infants of a first episode of genital herpes during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Rapid detection of herpes-simplex-virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

1 reference

7 January 2021

Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

Herpes simplex encephalitis: vidarabine therapy and diagnostic problems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904638-9

7 January 2021

10.1016/S0140-6736(00)04638-9

Identifiers

DOI

1 reference

30 July 2017

1 reference